ALDX earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -3.72. Updated 2026-07-23.
Aldeyra The (ALDX) Research Hub
Aldeyra The (ALDX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.34 USD (-10.67%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.72, market cap 0.10B. This hub links to the full technical, earnings and options research available for ALDX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.34 USD (-10.67%) |
| 52-week range | 1.33 USD – 2.53 USD |
| Trend regime | Range |
| 14-day RSI | 34.8 (Bearish) |
| Trailing P/E | -3.72 |
| Market cap | 0.10B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ALDX
Covered Call on ALDX: how it works, illustrative setup around the real 1.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALDX: how it works, illustrative setup around the real 1.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALDX: how it works, illustrative setup around the real 1.34 USD price, max profit/loss, breakeven and when to use it. Educational.
ALDX technical analysis: range, last 1.34 USD, RSI 34.8, 52w range 1.33 USD–2.53 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ALDX in?
Aldeyra The (ALDX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ALDX in an uptrend or downtrend?
As of 2026-09-11, ALDX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALDX's trailing P/E ratio?
ALDX's trailing P/E is -3.72, with a market cap of 0.10B. See the earnings research page for full valuation detail.
When does ALDX next report earnings?
ALDX is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.11 USD.